The usual starting dose of prednisone for polymyalgia rheumatica (PMR) is 15 mg per day, with a recommended range of 12.5 to 25 mg daily depending on your body size, symptom severity, and other health conditions. This is considered a low dose compared to what’s used for many other inflammatory conditions, and most people notice dramatic relief within days.
How the Starting Dose Is Determined
International guidelines from the European and American rheumatology societies recommend using the minimum effective dose to achieve remission, with 15 mg daily as the suggested starting point for an average patient. But doctors adjust within the 12.5 to 25 mg range based on individual factors.
If you have a smaller body frame, milder symptoms, uncontrolled diabetes, or elevated risk for steroid side effects, your doctor may start as low as 7.5 to 10 mg per day. On the other hand, if you’re larger or have severe symptoms, a starting dose of 20 to 25 mg daily is reasonable. The goal is always to use the lowest dose that controls your pain and stiffness, because every extra milligram adds up over months of treatment.
What to Expect in the First Few Weeks
Prednisone at these doses typically produces a rapid, sometimes dramatic improvement. Many people feel significantly better within a few days, and this quick response is actually one of the ways doctors confirm the diagnosis. If your symptoms don’t improve meaningfully within two to three weeks, your doctor may reconsider whether PMR is the correct diagnosis or whether the dose needs adjusting.
That said, up to 29 to 45% of patients don’t adequately respond to steroids within the first three to four weeks. This doesn’t necessarily mean the diagnosis is wrong, but it usually prompts further evaluation and possible dose changes.
The Tapering Process
PMR treatment isn’t about staying at the starting dose. Once your symptoms are controlled, the dose is gradually reduced in small steps. Tapering too quickly is one of the most common causes of flare-ups, so the process is deliberately slow. Most tapering schedules reduce the dose by 1 to 2.5 mg at a time, with each reduction held for several weeks before the next step down.
The total duration of treatment is longer than most people expect. In one study tracking PMR patients, the average time on steroids was 30 months. Patients whose blood inflammation markers were normal at diagnosis averaged about 22 months on treatment, while those with elevated markers averaged closer to three years before achieving drug-free remission. Some patients remain on low-dose steroids indefinitely.
Relapses During Tapering
Relapses are common with PMR, and they tend to happen during the tapering phase. If your symptoms return while your dose is being reduced, the standard approach is to go back to the dose you were taking before the flare, then taper again more slowly, typically returning to the relapse dose over four to eight weeks. This can feel frustrating, but it’s a normal part of managing the condition rather than a sign that treatment has failed.
Side Effects at PMR Doses
Even at 10 to 15 mg per day, prednisone can cause side effects that accumulate over months and years of use. The most commonly monitored ones include high blood pressure, osteoporosis, weight gain, cataracts, difficulty sleeping, and skin thinning or easy bruising. Because treatment lasts so long, these aren’t theoretical risks. They’re practical concerns that need regular monitoring.
Bone loss deserves special attention. Long-term steroid use is one of the leading causes of osteoporosis, and since PMR primarily affects people over 50, many are already at elevated risk. Calcium and vitamin D supplementation is recommended for essentially all patients on ongoing steroid therapy. Your doctor may also assess your bone density and consider additional bone-protective treatment depending on your risk profile.
When Steroid-Sparing Options Come In
For patients who keep relapsing during tapering or can’t get below a certain dose without symptoms returning, doctors sometimes add a second medication to help reduce the total amount of prednisone needed. Methotrexate has been used for this purpose for years, and newer biologic treatments targeting specific inflammatory pathways have shown promise.
In clinical trials, one biologic (sarilumab) reduced the total steroid exposure over a year from about 2 grams down to roughly 0.78 grams compared to placebo. That’s a meaningful reduction when you consider the cumulative toll of steroids over months of treatment. These medications aren’t first-line treatments, but they’re increasingly available for patients who struggle with long-term steroid dependence or experience significant side effects.